Drugs / AG01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05627960 | Feb 2022 → Jun 2026 overdue | hormone-resistant breast carcinoma, mesothelioma, non-small cell lung carcinoma, triple-negative breast carcinoma | A&G Pharmaceutical Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG01 | “This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors.” NCT05627960 ↗ |
| Modality | Monoclonal antibody | “AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line.” NCT05627960 ↗ |